Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis - 24/04/13
Correspondence to: Alan Menter, MD, Baylor Research Institute, 3900 Junius St, Suite 145, Dallas, TX 75246.Abstract |
Background |
Alefacept was the first biologic agent approved in the United States for the treatment of moderate to severe chronic plaque psoriasis (January 2003). Standard prescription is 12 weekly intramuscular doses. The mechanism of action involves the inhibition of T-cell activation and the selective induction of apoptosis of memory T cells. A proportion of patients responding to therapy have been reported to experience remissions of approximately 7 to 8 months, characterized by disease-free and treatment-free intervals.
Objective |
We sought to evaluate the efficacy and safety of alefacept treatment in patients with psoriasis during routine clinical practice.
Methods |
We conducted a retrospective chart analysis of data involving 201 patients and 296 courses of alefacept from February 2003 to January 2006. Standard informed consent was obtained.
Results |
Of the 62 patients (32.6%) who achieved an excellent response, 45% received dosage regimens defined as alternative and 73% had concomitant therapy in at least one of the treatment courses that they received. The average remission time of these patients who achieved an excellent response was approximately 7 months, with a maximum of up to 25 months. Adverse events were generally manageable and rarely led to treatment discontinuation.
Limitations |
Study data rely on retrospective analysis of chart-documented clinical examination findings, and patient compliance with visit schedules.
Conclusion |
Alefacept is a long-term treatment option for psoriasis with long-term remissions noted in a proportion of patients.
Le texte complet de cet article est disponible en PDF.Abbreviations used : BSA, IM, IV, UV
Plan
| Originally supported by Biogen Idec; Astellas Pharma US Inc acquired ownership of Amevive effective April 14, 2006, and has subsequently supported this work. |
|
| Disclosure: Dr Menter has received research support, lecture honoraria, or both from: Abbott Laboratories, Allergan Inc, Amgen Inc, Astellas, Biogen/IDEC, Centocor Inc, Cephalon, Collagenex Pharmaceuticals, CombinatoRx, Connetics Corp, Dow, Ferndale Laboratories Inc, Galderma, Genentech, Leo, Medicis, Photocure, Pierre Fabre, 3M Pharmaceuticals, UCB, Warner Chilcott, Wyeth, and XOMA. Dr Cather is a consultant for Abbott, Astellas, Biogen/IDEC, Centocor, and Genentech. Drs Jaracz and Franks are full-time employees of Astellas Pharma US Inc. Dr Perlmutter has no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 58 - N° 1
P. 116-124 - janvier 2008 Retour au numéro
Article précédent
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- Alan Menter, Stephen K. Tyring, Kenneth Gordon, Alexa B. Kimball, Craig L. Leonardi, Richard G. Langley, Bruce E. Strober, Martin Kaul, Yihua Gu, Martin Okun, Kim Papp
- Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period
- Andrew A. Nelson, Daniel J. Pearce, Alan B. Fleischer, Rajesh Balkrishnan, Steven R. Feldman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?